Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease

Patent metadata

Field	Value
Publication number	US-10172848-B2
Application number	US-201313921865-A
Country	US
Kind code	B2
Filing date	Jun 19, 2013
Priority date	Dec 22, 2010
Publication date	Jan 8, 2019
Grant date	Jan 8, 2019

Abstract

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.

First claim

What is claimed is:

1. A method of treating necrotizing enterocolitis in a subject in need of such treatment comprising administering to the subject one or more dose of a gap junction enhancing agent, wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 10 mg/kg, and wherein the gap junction enhancing agent is selected from the group consisting of
(a) a peptide comprising a sequence selected from the group consisting of SEQ ID NO:1-31; and
(b) a peptide analog selected from the group consisting of rotigaptide and GAP-134 ((2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid).

2. The method of claim 1 where the gap junction enhancing agent comprises a peptide having a sequence selected from the group consisting of SEQ ID NO:1-31.

3. The method of claim 1 where the gap junction enhancing agent is rotigaptide.

4. A method of reducing the risk of occurrence of necrotizing enterocolitis in a subject in need of such treatment comprising administering to the subject one or more dose of a gap junction enhancing agent, wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 10 mg/kg, and wherein the gap junction enhancing agent is selected from the group consisting of
(a) a peptide comprising a sequence selected from the group consisting of SEQ ID NO:1-31; and
(b) a peptide analog selected from the group consisting of rotigaptide and GAP-134 ((2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid).

5. The method of claim 4 where the gap junction enhancing agent comprises a peptide having a sequence selected from the group consisting of SEQ ID NO:1-31.

6. The method of claim 4 where the gap junction enhancing agent is rotigaptide.

7. A method of inducing increased migration of enterocytes in a subject diagnosed with necrotizing enterocolitis, the method comprising administering to the subject one or more dose of a gap junction enhancing agent, wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 10 mg/kg, and wherein the gap junction enhancing agent is selected from the group consisting of
(a) a peptide comprising a sequence selected from the group consisting of SEQ ID NO:1-31; and
(b) a peptide analog selected from the group consisting of rotigaptide and GAP-134 ((2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid).

8. The method of claim 7 where the gap junction enhancing agent comprises a peptide having a sequence selected from the group consisting of SEQ ID NO:1-31.

9. The method of claim 7 where the gap junction enhancing agent is rotigaptide.

10. The method of claim 1 , wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 5 mg/kg.

11. The method of claim 10 , wherein the one or more dose of the gap junction enhancing agent is between 0.1 mg/kg and 1 mg/kg.

12. The method of claim 4 , wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 5 mg/kg.

13. The method of claim 12 , wherein the one or more dose of the gap junction enhancing agent is between 0.1 mg/kg and 1 mg/kg.

14. The method of claim 7 , wherein the one or more dose of the gap junction enhancing agent is between 0.05 mg/kg and 5 mg/kg.

15. The method of claim 14 , wherein the one or more dose of the gap junction enhancing agent is between 0.1 mg/kg and 1 mg/kg.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Univ Of Pittsburgh—Of The Commonwealth Systems Of Higher Education

Inventors

• Hackam David J

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/47

  Quinolines; Isoquinolines · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• A61K38/16

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title